![](https://ml.globenewswire.com/media/562ba5bc-dbfd-4cd1-a8b3-ee2264fb3678/small/actuate-logo-png.png)
Actuate Therapeutics Announces Pricing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat …